Jardiance Generic: When Will Generic Empagliflozin Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Jardiance Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? 2032 to 2033 A wide window Why then?
- Has the FDA approved a generic? August 2022 Since discontinued Why not yet?
- When does the last patent end? December 2034 15 patents listed with the FDA Why is a generic expected sooner?
- Can you buy a generic today? Not yet No company lists one for sale
Generic empagliflozin is expected to be available between 2032 and 2033. None is for sale yet.
Why 2032 to 2033?
The brand company and a generic maker settled their patent fight and agreed on when a generic can launch. We rate it probable: more likely than not, but it can still move.
If Jardiance’s last patent runs to December 2034, how can a generic come sooner?
The 10 patents that run past the expected month, to December 2034 (11,666,590, 12,263,153, 12,427,162, 10,258,637 and 6 more), cover a way of using it. A patent like that protects one way of making or using the medicine, not the medicine itself. A generic company can often make its version a different way or leave that use off its label, or a court can rule the patent invalid or not infringed. Here, a settlement between the companies sets the date. Generic companies have been challenging Jardiance’s patents with the FDA since August 2018. That is why the expected month comes before the last protection ends. See the road to a generic
Why hasn’t the FDA approved a generic yet?
That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. 7 companies already hold a “tentative” approval, the FDA’s word for a generic that is ready but still blocked: Aizant (December 2020), Annora Pharma (January 2021), Laurus Generics Inc (June 2022) and 4 more. See who is lined up
Will the generic cost less?
Usually, and more so as more companies sell one. 21 companies have applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid over 95% less once six or more companies sold a generic, which would take the $11.19 pharmacies pay per tablet for Jardiance today to under $0.56. See the price estimate
What should I do now?
Keep taking Jardiance as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Jardiance by the Numbers
- Reason
- Settlement between companiesThe brand company and a generic maker settled their patent fight and agreed on when a generic can launch.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- Very strong 21 companies have filed, 14 first in line
- Brand sales
- $28.1B a yearBlockbuster
- FDA approved 2014 August 2014 FDA Orange Book
- Patents listed 15 last runs to December 2034 A generic is expected sooner, between 2032 and 2033. See why FDA Orange Book
- Pharmacies pay $11.19 per tablet, down 42.7% in a year NADAC, October 2026
- Medicare Part D spent $15.1B in 2025, for 3M people CMS Part D Spending by Drug
- Medicaid prescriptions 2.9M in the last four reported quarters, $2.3B CMS Medicaid drug utilization, to Q1 2026
Jardiance’s Road to a Generic
Jardiance has had the market to itself since the FDA approved it in August 2014 (Boehringer Ingelheim Pharmaceuticals Inc). Its FDA protection (pediatric) runs to December 2026. Its 15 listed patents run to December 2034. Generic companies have challenged its patents with the FDA since August 2018.
The first generic of Jardiance is expected between 2032 and 2033.
Why that month: the brand company and a generic maker settled their patent fight and agreed on when a generic can launch.
Why a Generic Can Come Before December 2034
The last listed patent runs to December 2034, but it covers a way of using it, not the medicine itself, which a generic can often work around or challenge. Dr. Brian explains
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Jardiance Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Jardiance’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 7,713,938 | The active ingredient; the product’s formulation | October 2027 with the pediatric extension | Active |
| 7,579,449 | The active ingredient | February 2029 with the pediatric extension | Active |
| 8,551,957 | A way of using it (U-1651) | April 2030 with the pediatric extension | Active |
| 12,115,179 | A way of using it (U-4023) | August 2030 with the pediatric extension | Active |
| 12,527,810 | A way of using it (U-4403) | October 2033 with the pediatric extension | Active |
| 11,666,590 | A way of using it (U-3691) | April 2034 | Active |
| 12,263,153 | A way of using it (U-4171) | April 2034 | Active |
| 12,427,162 | A way of using it (U-4287) | April 2034 | Active |
| 10,258,637 | A way of using it (U-2290) | October 2034 with the pediatric extension | Active |
| 11,090,323 | A way of using it (U-3191) | October 2034 with the pediatric extension | Active |
| 11,813,275 | A way of using it (U-3759, U-3760) | October 2034 with the pediatric extension | Active |
| 11,833,166 | A way of using it (U-3776, U-3777) | October 2034 with the pediatric extension | Active |
| 12,433,906 | A way of using it (U-4304, U-4293, U-4294, U-4295, U-4296) | October 2034 with the pediatric extension | Active |
| 9,949,997 | A way of using it (U-2292, U-3325, U-3199) | November 2034 with the pediatric extension | Active |
| 9,949,998 | A way of using it (U-2290) | December 2034 with the pediatric extension | Active |
| Exclusivity | What it means | Ends | Status |
|---|---|---|---|
| New patient population NPP | Three years of protection for a newly approved group of patients. | June 2026 | Ended |
| New use I-922 | Three years of protection for a newly approved use (indication). | September 2026 | Ended |
| Pediatric PED | Six more months, earned by studying the medicine in children. | December 2026 | Active |
Source: FDA Orange Book, application 204629. Patent numbers open the patent on Google Patents.
Patent Challenges to Jardiance
The first patent challenge to Jardiance reached the FDA in August 2018, from 14 companies on that first day. The FDA approved a first challenger’s generic in August 2022, and the list records no sale by a first challenger yet.
What Is a Patent Challenge?
A generic company that wants to sell its version before Jardiance’s patents run out can tell the FDA that a patent is invalid, or that its version does not infringe it. The FDA calls this a “Paragraph IV certification.” The brand company usually sues, and the FDA then generally cannot approve that generic for up to 30 months while the case runs. To reward going first, the companies that challenge first can get a 180-day head start: the FDA cannot approve the generics that came after them until it ends.
| Product | First challenged | Companies that day | 180-day head start | First challenger’s generic | Challenged patents run to | |
|---|---|---|---|---|---|---|
| Approved | On sale | |||||
| Tablets, 10 mg and 25 mg | August 2018 | 14 companies | First challenger eligible decided September 2022 | August 2022 | Not yet | June 2034 |
Source: the FDA’s Paragraph IV Patent Certifications list, as of September 2026. The FDA began posting the 180-day decisions and the first challenger’s approval and first sale in June 2019: an older entry it has not updated since reads “Not posted”, and “Not yet” means the list records no such event. “Companies that day” is the FDA’s count of challenges that arrived on the first day.
Who Is Lined Up to Make Generic Empagliflozin
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
21 companies have applied to the FDA to make generic empagliflozin.
The FDA has tentatively approved 7 companies’ generics, listed below. A tentative approval means the generic is ready, but a patent or exclusivity still stops the FDA from giving it final approval.
The FDA keeps the other applications private until it acts on them, so those companies are not named here.
First in line. 14 of them were first in line, all filing on the first day any company did: they can share 180 days on the market before the other generics, which is why being first matters.
Generic companies have challenged Jardiance’s patents with the FDA since August 2018: see the patent challenges.
Approved by the FDA
Not yet. The FDA has not approved a generic empagliflozin. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic empagliflozin for sale with the FDA.
| Company | Tentatively approved |
|---|---|
| Aizant | December 2020 |
| Annora Pharma | January 2021 |
| Laurus Generics Inc | June 2022 |
| Alkem Labs Ltd | September 2022 |
| Sun Pharm Inds Ltd | March 2023 |
| Ajanta Pharma Ltd | April 2025 |
| Aurobindo Pharma Limited | May 2026 |
| Company | First approved | Strengths | Rated |
|---|---|---|---|
| Zydus Pharmaceuticals USA Inc discontinued | August 2022 | 10MG, 25MG | – |
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Jardiance Price: What Pharmacies Pay and What Generics Usually Do
What Pharmacies Pay for Jardiance 10 mg tablet
$11.19 per tablet in October 2026, down 42.7% from a year earlier.
Hover over or tap anywhere on the chart to see that month’s price.
- Jardiance 10 mg tablet $11.19 per tablet
- Jardiance 25 mg tablet $11.19 per tablet
See the numbers
| Month | Pharmacies paid per tablet |
|---|---|
| October 2026 | $11.19 |
| September 2026 | $11.19 |
| August 2026 | $11.19 |
| July 2026 | $11.19 |
| June 2026 | $11.19 |
| May 2026 | $11.20 |
| April 2026 | $11.20 |
| March 2026 | $11.20 |
| February 2026 | $11.20 |
| January 2026 | $11.20 |
| February 2024 | $19.53 |
| January 2024 | $19.53 |
NADAC: the national average price retail pharmacies pay to buy the medicine (CMS survey, updated weekly), the last price of each month for one package. It is not what you pay: that depends on your insurance or discount card.
What a Generic Could Cost
How we estimate it. We start from what pharmacies pay for Jardiance today: $11.19 per tablet for Jardiance 10 mg tablet in October 2026, from the national NADAC survey. Then we apply the FDA’s finding of how far that price usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017). Jardiance has 21 companies lined up, so our estimate uses the figure for six or more companies. More companies would bring the price lower; fewer, less of a drop.
Dollar figures apply FDA’s median drops to the $11.19 pharmacies pay per tablet today. An estimate from the pattern, not a price quote: what you pay depends on your insurance or discount card.
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Jardiance
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Jardiance, before manufacturer rebates.
- $1.3B
- January to March 2026, the latest CMS has posted
For 2,256,124 people, about $387 per prescription fill - $15.1B
- 2025, the whole year
For 2,977,956 people, about $1,091 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $1,338,904,929 | 2,256,124 | $386.83 |
| 2025 | $15,087,584,932 | 2,977,956 | $1,091.19 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Jardiance only, so no generic is counted in it. What CMS says it is used for: Empagliflozin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems.
Medicaid Prescriptions by Quarter
2,912,818 prescriptions in the four quarters to Q1 2026, $2.3B paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 681,490 | $370,917,211 |
| Q4 2025 | 739,784 | $637,066,585 |
| Q3 2025 | 771,264 | $662,546,186 |
| Q2 2025 | 720,280 | $612,309,859 |
| Q1 2025 | 713,234 | $606,120,462 |
Source: CMS Medicaid State Drug Utilization Data, over Jardiance’s own package codes.
Jardiance Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| 10MG | Tablet | Oral | August 2014 | Prescription reference product |
| 25MG | Tablet | Oral | August 2014 | Prescription reference product |
Source: FDA Orange Book, Boehringer Ingelheim Pharmaceuticals Inc. Listed for sale today by Boehringer Ingelheim Pharmaceuticals, Inc., A-S Medication Solutions, Cardinal Health 107, LLC, Remedyrepack Inc. and 2 more (FDA NDC Directory).
Jardiance NDC Codes and Packages
Each Jardiance package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 70518-1986-00 | 10 mg tablet, film coated | bottle of 90 tablets | Remedyrepack Inc. |
| 70518-2447-00 | 25 mg tablet, film coated | bottle of 90 tablets | Remedyrepack Inc. |
| 00597-0152-07 | EMPAGLIFLOZIN 10 mg/1 tablet, film coated | bottle of 7 tablets | Boehringer Ingelheim Pharmaceuticals, Inc. |
| 00597-0152-07 | EMPAGLIFLOZIN 10 mg/1 tablet, film coated | bottle of 7 tablets | Boehringer Ingelheim Pharmaceuticals, Inc. |
| 00597-0152-30 | EMPAGLIFLOZIN 10 mg/1 tablet, film coated | bottle of 30 tablets | Boehringer Ingelheim Pharmaceuticals, Inc. |
| 00597-0152-30 | EMPAGLIFLOZIN 10 mg/1 tablet, film coated | bottle of 30 tablets | Boehringer Ingelheim Pharmaceuticals, Inc. |
| 00597-0152-37 | EMPAGLIFLOZIN 10 mg/1 tablet, film coated | carton of 30 blister packs of 1 tablet | Boehringer Ingelheim Pharmaceuticals, Inc. |
| 00597-0152-37 | EMPAGLIFLOZIN 10 mg/1 tablet, film coated | carton of 30 blister packs of 1 tablet | Boehringer Ingelheim Pharmaceuticals, Inc. |
Show the other 39 Jardiance packages
| NDC | Product | Package | Company |
|---|---|---|---|
| 00597-0152-70 | EMPAGLIFLOZIN 10 mg/1 tablet, film coated | carton of 7 blister packs of 1 tablet | Boehringer Ingelheim Pharmaceuticals, Inc. |
| 00597-0152-90 | EMPAGLIFLOZIN 10 mg/1 tablet, film coated | bottle of 90 tablets | Boehringer Ingelheim Pharmaceuticals, Inc. |
| 00597-0152-90 | EMPAGLIFLOZIN 10 mg/1 tablet, film coated | bottle of 90 tablets | Boehringer Ingelheim Pharmaceuticals, Inc. |
| 50090-4492-00 | EMPAGLIFLOZIN 10 mg/1 tablet, film coated | bottle of 90 tablets | A-S Medication Solutions |
| 50090-4492-00 | EMPAGLIFLOZIN 10 mg/1 tablet, film coated | bottle of 90 tablets | A-S Medication Solutions |
| 50090-4492-01 | EMPAGLIFLOZIN 10 mg/1 tablet, film coated | bottle of 30 tablets | A-S Medication Solutions |
| 50090-4492-01 | EMPAGLIFLOZIN 10 mg/1 tablet, film coated | bottle of 30 tablets | A-S Medication Solutions |
| 50090-6452-00 | EMPAGLIFLOZIN 10 mg/1 tablet, film coated | bottle of 90 tablets | A-S Medication Solutions |
| 50090-6452-00 | EMPAGLIFLOZIN 10 mg/1 tablet, film coated | bottle of 90 tablets | A-S Medication Solutions |
| 55154-0411-08 | EMPAGLIFLOZIN 10 mg/1 tablet, film coated | bottle of 720 tablets | Cardinal Health 107, LLC |
| 55154-0411-08 | EMPAGLIFLOZIN 10 mg/1 tablet, film coated | bottle of 720 tablets | Cardinal Health 107, LLC |
| 71610-0900-09 | EMPAGLIFLOZIN 10 mg/1 tablet, film coated | bottle of 9,000 tablets | Aphena Pharma Solutions - Tennessee, LLC |
| 71610-0900-97 | EMPAGLIFLOZIN 10 mg/1 tablet, film coated | bottle of 4,500 tablets | Aphena Pharma Solutions - Tennessee, LLC |
| 00597-0153-07 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 7 tablets | Boehringer Ingelheim Pharmaceuticals, Inc. |
| 00597-0153-07 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 7 tablets | Boehringer Ingelheim Pharmaceuticals, Inc. |
| 00597-0153-30 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 30 tablets | Boehringer Ingelheim Pharmaceuticals, Inc. |
| 00597-0153-30 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 30 tablets | Boehringer Ingelheim Pharmaceuticals, Inc. |
| 00597-0153-37 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | carton of 30 blister packs of 1 tablet | Boehringer Ingelheim Pharmaceuticals, Inc. |
| 00597-0153-37 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | carton of 30 blister packs of 1 tablet | Boehringer Ingelheim Pharmaceuticals, Inc. |
| 00597-0153-70 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | carton of 7 blister packs of 1 tablet | Boehringer Ingelheim Pharmaceuticals, Inc. |
| 00597-0153-90 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 90 tablets | Boehringer Ingelheim Pharmaceuticals, Inc. |
| 00597-0153-90 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 90 tablets | Boehringer Ingelheim Pharmaceuticals, Inc. |
| 50090-4384-00 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 90 tablets | A-S Medication Solutions |
| 50090-4384-00 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 90 tablets | A-S Medication Solutions |
| 50090-4384-01 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 30 tablets | A-S Medication Solutions |
| 50090-4384-01 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 30 tablets | A-S Medication Solutions |
| 50090-6457-00 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 90 tablets | A-S Medication Solutions |
| 50090-6457-00 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 90 tablets | A-S Medication Solutions |
| 55154-0412-08 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 990 tablets | Cardinal Health 107, LLC |
| 55154-0412-08 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 990 tablets | Cardinal Health 107, LLC |
| 67296-2324-03 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 30 tablets | Redpharm Drug |
| 71610-0177-09 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 9,000 tablets | Aphena Pharma Solutions - Tennessee, LLC |
| 71610-0177-09 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 9,000 tablets | Aphena Pharma Solutions - Tennessee, LLC |
| 71610-0177-15 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 15 tablets | Aphena Pharma Solutions - Tennessee, LLC |
| 71610-0177-42 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 1,800 tablets | Aphena Pharma Solutions - Tennessee, LLC |
| 71610-0177-42 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 1,800 tablets | Aphena Pharma Solutions - Tennessee, LLC |
| 71610-0177-45 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 45 tablets | Aphena Pharma Solutions - Tennessee, LLC |
| 71610-0177-81 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 1,080 tablets | Aphena Pharma Solutions - Tennessee, LLC |
| 71610-0177-99 | EMPAGLIFLOZIN 25 mg/1 tablet, film coated | bottle of 5,040 tablets | Aphena Pharma Solutions - Tennessee, LLC |
Source: the FDA NDC Directory, current listings only. Only packages sold under Jardiance’s own FDA approval (NDA 204629) are listed, never a generic. Some codes belong to companies that repackage Jardiance: it is the same medicine in a different package.
What a Generic Jardiance Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Jardiance as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Jardiance”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Jardiance
Is there a generic for Jardiance right now?
No. As of October 9, 2026 no generic empagliflozin is listed for sale in the FDA NDC Directory. 1 generic version is FDA-approved (Orange Book), which usually means it is waiting on patents or on the maker’s own launch plans.
When will Jardiance go generic?
2032 to 2033 is the expected window, and that is probable but not certain. The brand company and a generic maker settled their patent fight and agreed on when a generic can launch. The last listed patent runs to December 2034, but it covers a way of using it, not the medicine itself, which a generic can often work around or challenge.
Will generic empagliflozin be the same as Jardiance?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. 21 companies have applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid over 95% less once six or more companies sold a generic, which would take the $11.19 pharmacies pay per tablet for Jardiance today to under $0.56. That is a pattern from past launches, not a prediction for this one.
Has the FDA approved a generic Jardiance?
Not yet. The FDA Orange Book lists no approved generic version of Jardiance that is still marketed.
When does the Jardiance patent expire?
The FDA Orange Book lists 15 patents for Jardiance; the last runs to December 2034, counting a six-month pediatric extension. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected window on this page (2032 to 2033) weighs all of that.
Has anyone challenged the Jardiance patents?
Yes. The first patent challenge to Jardiance reached the FDA in August 2018, from 14 companies on that first day. The FDA approved a first challenger’s generic in August 2022, and the list records no sale by a first challenger yet. A patent challenge (a “Paragraph IV certification”) is a generic company telling the FDA that a patent listed for the brand is invalid or will not be infringed by its version. The first companies to file one can earn a 180-day head start, during which the FDA cannot approve the generics that filed after them.
How much does Jardiance cost now?
Pharmacies paid about $11.19 per tablet for Jardiance 10 mg tablet in October 2026, by the national survey of what pharmacies pay (NADAC). That is the pharmacy’s cost, not your price: what you pay depends on your insurance or discount card.
Changes to This Projection
- First generic expected 2032 to 2033 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- CaprelsaVandetanibAugust 2028
- GiaprezaAngiotensin II Acetate2031 to 2032
- ZerbaxaCeftolozane and TazobactamFebruary 2036
- TrudhesaDihydroergotamine MesylateJanuary 2039
- QinlockRipretinibFebruary 2041
- LynavoyLinerixibatOctober 2041
About Jardiance
- Generic name empagliflozin
- How it is taken By mouth
- Company Boehringer Ingelheim Pharmaceuticals Inc
- Patent challenges Since August 2018 (FDA)
- More drugs Brand-name drugs starting with J
- Have a question? A pharmacist answers, free. Ask about Jardiance
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA Paragraph IV Patent Certifications list, NADAC (CMS), CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.